Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities.
Liu Y, Wang C, Wang G, Sun Y, Deng Z, Chen L, Chen K, Tickner J, Kenny J, Song D, Zhang Q, Wang H, Chen Z, Zhou C, He W, Xu J.
Liu Y, et al. Among authors: zhang q.
Theranostics. 2019 Jul 3;9(16):4648-4662. doi: 10.7150/thno.35414. eCollection 2019.
Theranostics. 2019.
PMID: 31367247
Free PMC article.